Abstract
Chronic liver disease results from a variety of causes such as hepatitis virus infections, autoimmune processes and alcohol consumption. Its complications include fat deposition, hemodynamic changes and fibrosis. Clinically there may be progression to portal-hypertension and porto-systemic encephalopathy. Pioneering research from the laboratory of Kunos at NIH has stressed the importance of endocannabinoids (ECs) as mediators of some of the pathological processes in chronic liver disease. The present review summarizes the literature on the association between ECs and liver disease, as well as the therapeutic potential of ECs and exogenous cannabinoids in liver disease with emphasis on hepatic encephalopathy.
Keywords: Endocannabinoids, Liver Disease, Hepatic Encephalopathy, Chronic liver, autoimmune processes, hemodynamic, fibrosis, portal-hypertension, pathological processes
Current Pharmaceutical Design
Title: Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Volume: 14 Issue: 23
Author(s): Iddo Magen, Yosefa Avraham, Elliot Berry and Raphael Mechoulam
Affiliation:
Keywords: Endocannabinoids, Liver Disease, Hepatic Encephalopathy, Chronic liver, autoimmune processes, hemodynamic, fibrosis, portal-hypertension, pathological processes
Abstract: Chronic liver disease results from a variety of causes such as hepatitis virus infections, autoimmune processes and alcohol consumption. Its complications include fat deposition, hemodynamic changes and fibrosis. Clinically there may be progression to portal-hypertension and porto-systemic encephalopathy. Pioneering research from the laboratory of Kunos at NIH has stressed the importance of endocannabinoids (ECs) as mediators of some of the pathological processes in chronic liver disease. The present review summarizes the literature on the association between ECs and liver disease, as well as the therapeutic potential of ECs and exogenous cannabinoids in liver disease with emphasis on hepatic encephalopathy.
Export Options
About this article
Cite this article as:
Magen Iddo, Avraham Yosefa, Berry Elliot and Mechoulam Raphael, Endocannabinoids in Liver Disease and Hepatic Encephalopathy, Current Pharmaceutical Design 2008; 14 (23) . https://dx.doi.org/10.2174/138161208785740063
DOI https://dx.doi.org/10.2174/138161208785740063 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery Interaction Between Genetic Polymorphisms in Renin-Angiotensin System (RAS) and Therapeutic Efficacy of RAS Blockade in IgA Nephropathy
Current Pharmacogenomics Cardiovascular Effects of Liraglutide
Current Hypertension Reviews Is HIV Involved in the Pathogenesis of Non-Infectious Pulmonary Complications in Infected Patients?
Current HIV Research The Neonatal Kidney: Implications for Drug Metabolism and Elimination
Current Drug Metabolism Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan
Current Gene Therapy Obesity in China: What are the Causes?
Current Pharmaceutical Design Trajectories of Age-Related Cognitive Decline and Potential Associated Factors of Cognitive Function in Senior Citizens of Beijing
Current Alzheimer Research Vascular Endothelial Dysfunction and Nutritional Compounds in Early Type 1 Diabetes
Current Diabetes Reviews Dehydrogenases/Reductases for the Synthesis of Chiral Pharmaceutical Intermediates
Current Organic Chemistry Assessment of Possible Drug Interactions in Patients with Psoriasis and Associated Comorbid Medical Conditions: An Observational Study
Reviews on Recent Clinical Trials Development and Validation of a Simple High-Performance Liquid Chromatography Method for Estimation of Felodipine in Rabbit Plasma: Application to Pharmacokinetic Study
Current Pharmaceutical Analysis Chlorella vulgaris: A Multifunctional Dietary Supplement with Diverse Medicinal Properties
Current Pharmaceutical Design Follicular Cysts: A Single Sign and Different Diseases. A View from Comparative Medicine
Current Pharmaceutical Design Targeting Vascular Disease in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Novel Benefits of Sodium Restriction in Chronic Kidney Disease
Current Hypertension Reviews Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway
Current Neuropharmacology